The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis
Context: When nucleos(t)ide analogues (NAs) were applied clinically to manage chronic hepatitis B virus infection, the prognosis of chronic hepatitis B (CHB) patients greatly improved. However, certain CHB patients with normal alanine aminotransferase (ALT) levels were not used to be considered as t...
Saved in:
Published in | Hepatitis monthly Vol. 22; no. 1 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.12.2022
|
Online Access | Get full text |
Cover
Loading…
Abstract | Context: When nucleos(t)ide analogues (NAs) were applied clinically to manage chronic hepatitis B virus infection, the prognosis of chronic hepatitis B (CHB) patients greatly improved. However, certain CHB patients with normal alanine aminotransferase (ALT) levels were not used to be considered as the population with the need for antiviral treatment. Objectives: This systematic review and meta-analysis collected and analyzed data from clinical trials to assess and compare the efficacy of antiviral treatment among patients with elevated and normal ALT levels. Methods: A systematic search was performed to gather studies published from 1990.01 to 2022.08 in PubMed and Web of Science databases. The quality of the literature was assessed, and 16 studies were included for further analysis. Basic information on included studies and study populations was collected. A meta-analysis was carried out to evaluate three major outcomes of viral response, hepatitis B envelope antigen (HBeAg) loss, and HBeAg seroconversion after NAs treatment based on data extracted from these studies. Odds ratios (ORs) with 95% confidence intervals (CIs) for all outcomes were calculated using fixed-effects models. Results: In the 16 relevant studies, 5,345 patients met the inclusion criteria, including 3,687 patients receiving NAs treatment. All patients were grouped into one with elevated ALT and another with normal ALT based on whether their pretreatment ALT levels > 1*upper limit of normal (ULN). For patients receiving lamivudine, the viral response showed no significant difference between the groups with elevated and normal ALT levels (pooled log OR: 0.51 [-0.23 - 1.26], P = 0.79); the pooled log OR for HBeAg loss was 1.19 (0.63 - 1.76, P = 0.03) and pooled log OR for HBeAg seroconversion was 2.19 (0.91 - 3.47, P = 0.40). For patients receiving first-line therapy with tenofovir disoproxil fumarate (TDF) and entecavir (ETV), the viral response showed no significant difference between the two groups: Pooled log OR (0.38 [-0.22 - 0.97], P = 0.10). The pooled log OR for HBeAg loss and HBeAg seroconversion was (-0.07 [-0.81 - 0.67], P = 0.68) and (0.40 [-0.84 - 1.63], P = 0.88), respectively. Conclusions: The efficacies of first-line therapy with TDF and ETV treatments were similar in groups with elevated and normal ALT levels for the outcomes of viral response and HBeAg loss. These findings may support further treatment of CHB patients with normal ALT levels. |
---|---|
AbstractList | Context: When nucleos(t)ide analogues (NAs) were applied clinically to manage chronic hepatitis B virus infection, the prognosis of chronic hepatitis B (CHB) patients greatly improved. However, certain CHB patients with normal alanine aminotransferase (ALT) levels were not used to be considered as the population with the need for antiviral treatment. Objectives: This systematic review and meta-analysis collected and analyzed data from clinical trials to assess and compare the efficacy of antiviral treatment among patients with elevated and normal ALT levels. Methods: A systematic search was performed to gather studies published from 1990.01 to 2022.08 in PubMed and Web of Science databases. The quality of the literature was assessed, and 16 studies were included for further analysis. Basic information on included studies and study populations was collected. A meta-analysis was carried out to evaluate three major outcomes of viral response, hepatitis B envelope antigen (HBeAg) loss, and HBeAg seroconversion after NAs treatment based on data extracted from these studies. Odds ratios (ORs) with 95% confidence intervals (CIs) for all outcomes were calculated using fixed-effects models. Results: In the 16 relevant studies, 5,345 patients met the inclusion criteria, including 3,687 patients receiving NAs treatment. All patients were grouped into one with elevated ALT and another with normal ALT based on whether their pretreatment ALT levels > 1*upper limit of normal (ULN). For patients receiving lamivudine, the viral response showed no significant difference between the groups with elevated and normal ALT levels (pooled log OR: 0.51 [-0.23 - 1.26], P = 0.79); the pooled log OR for HBeAg loss was 1.19 (0.63 - 1.76, P = 0.03) and pooled log OR for HBeAg seroconversion was 2.19 (0.91 - 3.47, P = 0.40). For patients receiving first-line therapy with tenofovir disoproxil fumarate (TDF) and entecavir (ETV), the viral response showed no significant difference between the two groups: Pooled log OR (0.38 [-0.22 - 0.97], P = 0.10). The pooled log OR for HBeAg loss and HBeAg seroconversion was (-0.07 [-0.81 - 0.67], P = 0.68) and (0.40 [-0.84 - 1.63], P = 0.88), respectively. Conclusions: The efficacies of first-line therapy with TDF and ETV treatments were similar in groups with elevated and normal ALT levels for the outcomes of viral response and HBeAg loss. These findings may support further treatment of CHB patients with normal ALT levels. |
Author | Peng, Jie Hu, Meixin Kang, Zixin Chen, Hongjie Lin, Xiaoli Wu, Houji Liao, Guichan Qian, Zhe |
Author_xml | – sequence: 1 givenname: Zhe surname: Qian fullname: Qian, Zhe – sequence: 2 givenname: Meixin surname: Hu fullname: Hu, Meixin – sequence: 3 givenname: Houji surname: Wu fullname: Wu, Houji – sequence: 4 givenname: Hongjie surname: Chen fullname: Chen, Hongjie – sequence: 5 givenname: Guichan surname: Liao fullname: Liao, Guichan – sequence: 6 givenname: Zixin surname: Kang fullname: Kang, Zixin – sequence: 7 givenname: Xiaoli surname: Lin fullname: Lin, Xiaoli – sequence: 8 givenname: Jie surname: Peng fullname: Peng, Jie |
BookMark | eNo1kMtKw0AUhgepYFtduz0vEDuXZDJxF0u1QrygEdyFyWSGjORSZkJLtj65Ka2r88P5L_At0KzrO43QLcF3kSB0VeudHNq-CwhNBOMXaE5iFgUsxGJ21iRk31do4f0PxpHAMZ2j37zWsDHGKqlG6A2k3WD31skGcqenQt0NYHoH69r1nVWwPc7YwXp4gPdJTX8PBzvU8Nq7doqlWQ6Z3uvG30MKn6MfdDv5FHzovdUHkF0FL3qQgexkM3rrr9GlkY3XN-e7RF-Pm3y9DbK3p-d1mgWKMj4EUgkVJgmRhhoVK1pVnLFY4DDmYZlQxWMuGOWiKiuchFyUkigsk1JHODSMUbZEq1Ovcr33Tpti52wr3VgQXBwRFv8IixNC9gfUc2l5 |
Cites_doi | 10.1097/MD.0000000000004433 10.1002/hep.28015 10.1016/j.clinre.2020.05.011 10.1111/j.1365-2893.2011.01461.x 10.1016/j.jhep.2009.07.015 10.1053/jhep.2002.34294 10.1038/ajg.2009.248 10.1016/j.cgh.2007.01.005 10.1111/apt.15741 10.1002/hep.20926 10.1016/j.ejim.2020.10.022 10.1056/NEJMoa033364 10.1136/gut.2005.089722 10.1016/j.jhep.2007.07.022 10.1136/gutjnl-2017-314904 10.1016/s0140-6736(81)90585-7 10.1111/jvh.12613 10.1111/apt.16097 10.1097/MCG.0000000000000544 10.1007/s12072-015-9675-4 10.1002/hep.25818 10.1111/apt.16067 10.1002/jcb.27959 10.1016/j.jhep.2017.03.021 10.1002/hep.23424 10.1016/s2468-1253(18)30056-6 10.1097/01.inf.0000126412.93562.f5 10.1002/hep.30257 10.1016/j.amjmed.2003.12.040 10.3760/cma.j.issn.1007-3418.2019.12.007 10.1111/j.1440-1746.2005.03577.x 10.1016/j.jhep.2011.11.030 10.1111/apt.15311 10.1016/s1542-3565(04)00017-5 10.1186/1471-230X-5-29 10.1136/gut.2005.065136 10.1002/hep.22841 10.1002/hep.21724 10.1053/j.gastro.2008.02.075 10.1016/j.antiviral.2020.104953 10.1007/s00535-020-01680-0 10.3855/jidc.2759 10.1001/jama.295.1.65 10.1053/j.gastro.2014.01.044 10.1002/hep.510300313 10.1016/j.cgh.2020.04.091 10.1016/j.cgh.2014.07.019 10.1177/135965350901400507 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.5812/hepatmon-129836 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1735-3408 |
ExternalDocumentID | 10_5812_hepatmon_129836 |
GroupedDBID | --- 29I 2WC 3V. 53G 5GY 5VS 7X7 8FI 8G5 8R4 8R5 AAWTL AAYXX ABDBF ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BENPR BPHCQ BVXVI CITATION CWDGH DIK E3Z EBD EOJEC ESX FYUFA GROUPED_DOAJ GUQSH HYE KQ8 M2O M~E OBODZ OK1 PQQKQ PROAC Q2X RNS RPM TR2 TUS UKHRP ~8M |
ID | FETCH-LOGICAL-c236t-ac8c4991af2fc7c2dd6337804764b92c67683268dbd09468ba1c0a9be504f3323 |
ISSN | 1735-143X |
IngestDate | Fri Aug 23 00:30:26 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c236t-ac8c4991af2fc7c2dd6337804764b92c67683268dbd09468ba1c0a9be504f3323 |
OpenAccessLink | https://brieflands.com/articles/hepatmon-129836.pdf |
ParticipantIDs | crossref_primary_10_5812_hepatmon_129836 |
PublicationCentury | 2000 |
PublicationDate | 2022-12-01 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Hepatitis monthly |
PublicationYear | 2022 |
References | key-A129836REF45-45 key-A129836REF8-8 key-A129836REF47-47 key-A129836REF20-20 key-A129836REF7-7 key-A129836REF22-22 key-A129836REF24-24 key-A129836REF6-6 key-A129836REF26-26 key-A129836REF28-28 key-A129836REF5-5 key-A129836REF9-9 key-A129836REF30-30 key-A129836REF32-32 key-A129836REF34-34 key-A129836REF36-36 key-A129836REF11-11 key-A129836REF38-38 key-A129836REF13-13 key-A129836REF15-15 key-A129836REF17-17 key-A129836REF19-19 key-A129836REF41-41 key-A129836REF43-43 key-A129836REF44-44 key-A129836REF46-46 key-A129836REF48-48 key-A129836REF23-23 Lee JM (key-A129836REF21-21) 2009; 14 key-A129836REF25-25 key-A129836REF27-27 key-A129836REF29-29 key-A129836REF31-31 key-A129836REF33-33 key-A129836REF35-35 key-A129836REF37-37 key-A129836REF10-10 key-A129836REF39-39 key-A129836REF12-12 key-A129836REF14-14 key-A129836REF16-16 key-A129836REF18-18 key-A129836REF4-4 key-A129836REF3-3 key-A129836REF2-2 key-A129836REF40-40 key-A129836REF1-1 key-A129836REF42-42 |
References_xml | – ident: key-A129836REF45-45 doi: 10.1097/MD.0000000000004433 – ident: key-A129836REF18-18 doi: 10.1002/hep.28015 – ident: key-A129836REF26-26 doi: 10.1016/j.clinre.2020.05.011 – ident: key-A129836REF20-20 doi: 10.1111/j.1365-2893.2011.01461.x – ident: key-A129836REF8-8 doi: 10.1016/j.jhep.2009.07.015 – ident: key-A129836REF23-23 doi: 10.1053/jhep.2002.34294 – ident: key-A129836REF34-34 doi: 10.1038/ajg.2009.248 – ident: key-A129836REF28-28 doi: 10.1016/j.cgh.2007.01.005 – ident: key-A129836REF27-27 doi: 10.1111/apt.15741 – ident: key-A129836REF33-33 doi: 10.1002/hep.20926 – ident: key-A129836REF41-41 doi: 10.1016/j.ejim.2020.10.022 – ident: key-A129836REF48-48 doi: 10.1056/NEJMoa033364 – ident: key-A129836REF13-13 doi: 10.1136/gut.2005.089722 – ident: key-A129836REF35-35 doi: 10.1016/j.jhep.2007.07.022 – ident: key-A129836REF42-42 doi: 10.1136/gutjnl-2017-314904 – ident: key-A129836REF38-38 doi: 10.1016/s0140-6736(81)90585-7 – ident: key-A129836REF6-6 doi: 10.1111/jvh.12613 – ident: key-A129836REF9-9 doi: 10.1111/apt.16097 – ident: key-A129836REF36-36 doi: 10.1097/MCG.0000000000000544 – ident: key-A129836REF3-3 doi: 10.1007/s12072-015-9675-4 – ident: key-A129836REF22-22 doi: 10.1002/hep.25818 – ident: key-A129836REF37-37 doi: 10.1111/apt.16067 – ident: key-A129836REF44-44 doi: 10.1002/jcb.27959 – ident: key-A129836REF2-2 doi: 10.1016/j.jhep.2017.03.021 – ident: key-A129836REF25-25 doi: 10.1002/hep.23424 – ident: key-A129836REF1-1 doi: 10.1016/s2468-1253(18)30056-6 – ident: key-A129836REF17-17 doi: 10.1097/01.inf.0000126412.93562.f5 – ident: key-A129836REF5-5 doi: 10.1002/hep.30257 – ident: key-A129836REF39-39 doi: 10.1016/j.amjmed.2003.12.040 – ident: key-A129836REF11-11 doi: 10.3760/cma.j.issn.1007-3418.2019.12.007 – ident: key-A129836REF16-16 doi: 10.1111/j.1440-1746.2005.03577.x – ident: key-A129836REF29-29 doi: 10.1016/j.jhep.2011.11.030 – ident: key-A129836REF43-43 doi: 10.1111/apt.15311 – ident: key-A129836REF19-19 doi: 10.1016/s1542-3565(04)00017-5 – ident: key-A129836REF12-12 doi: 10.1186/1471-230X-5-29 – ident: key-A129836REF40-40 doi: 10.1136/gut.2005.065136 – ident: key-A129836REF7-7 doi: 10.1002/hep.22841 – ident: key-A129836REF30-30 doi: 10.1002/hep.21724 – ident: key-A129836REF32-32 doi: 10.1053/j.gastro.2008.02.075 – ident: key-A129836REF24-24 doi: 10.1016/j.antiviral.2020.104953 – ident: key-A129836REF46-46 doi: 10.1007/s00535-020-01680-0 – ident: key-A129836REF10-10 doi: 10.3855/jidc.2759 – ident: key-A129836REF47-47 doi: 10.1001/jama.295.1.65 – ident: key-A129836REF14-14 doi: 10.1053/j.gastro.2014.01.044 – ident: key-A129836REF15-15 doi: 10.1002/hep.510300313 – ident: key-A129836REF4-4 doi: 10.1016/j.cgh.2020.04.091 – ident: key-A129836REF31-31 doi: 10.1016/j.cgh.2014.07.019 – volume: 14 start-page: 705 issue: 5 year: 2009 ident: key-A129836REF21-21 publication-title: Antivir Ther. doi: 10.1177/135965350901400507 contributor: fullname: Lee JM |
SSID | ssj0058072 |
Score | 2.3154259 |
Snippet | Context: When nucleos(t)ide analogues (NAs) were applied clinically to manage chronic hepatitis B virus infection, the prognosis of chronic hepatitis B (CHB)... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | The Efficacy of Antiviral Treatment for Chronic Hepatitis B Patients with Normal ALT Levels: A Systematic Review and Meta-analysis |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBXbDZReSpq2NG0T5tBDIbj1SrYk97abD5aSBEo3dOllkWQ56xy8oXGg9Nb-8owsf3VJIMnFGGFmV37P0oyYeUPIB8ZZpLJQBUynAgMU_OYSaU2QMq2oNCnPqh5LJ6d8ehZ9ncfzweBvv7qk1J_Mn1vrSh6DKo4hrq5K9gHItkZxAO8RX7wiwni9N8aHTgPC9Wx3LmXhekFUJfdt_rhLI6wVcHGPcfnTZX61N3Ha_HlX3XbqXFcE63i2d-zSiK58xfr3Tue5VuCv8jJsqQJVq5n0vdvOPr6Cctllin7L_Tnrz2WPR9VZrM1_5y0_f1Rj09X1Rd6lHfh1cboqzi9y2z-koLSX8OHXVcHiAF2zud92ujEWhbK_GFO6Trr1NT5GlwSBWboZ4WTwlxLJblHTXtvl2txDjHqciUVjYOENPCEbVCRxPCQb48nB5KjZzmMZVh3A2hl4fShn4vPaf-i5Nj0fZbZJntfBBYw9U16QgS22yNOTOn3iJfmHhIGGMLDKoCUMtIQBJAzUhIEWUJhAQxhwhAFPGEDCgCfMFxhDRxfwdAGkC_xHl1fk7Ohwtj8N6iYcgaGMl4Ey0mBUPFIZzYwwNE05Y061SvBIJ9RwjFcxBJCpTsMk4lKrkQlVom0cRhljlL0mw2JV2DcEqJQ6lCLSuKdGimlJBbeUi5ESsWtLsE0-Nu9vcem1VhZ3oPX2_o--I886Rr4nw_LXtd1BR7LUuzXUN2Z8d_E |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Efficacy+of+Antiviral+Treatment+for+Chronic+Hepatitis+B+Patients+with+Normal+ALT+Levels%3A+A+Systematic+Review+and+Meta-analysis&rft.jtitle=Hepatitis+monthly&rft.au=Qian%2C+Zhe&rft.au=Hu%2C+Meixin&rft.au=Wu%2C+Houji&rft.au=Chen%2C+Hongjie&rft.date=2022-12-01&rft.issn=1735-143X&rft.eissn=1735-3408&rft.volume=22&rft.issue=1&rft_id=info:doi/10.5812%2Fhepatmon-129836&rft.externalDBID=n%2Fa&rft.externalDocID=10_5812_hepatmon_129836 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1735-143X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1735-143X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1735-143X&client=summon |